TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7709902

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing elastomers
Number of subjects: 4

Group type: COMPARATOR
Intervention: Conventional elastomers
Number of subjects: 4
Study: 2491219

Group type: EXPERIMENTAL
Intervention: Calcitonin 0.0175 iu/kg per min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Calcitonin 0.0350 iu/kg per min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 331627

Group type: COMPARATOR
Intervention: Amikacin sulfate (15 mg./Kg.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amikacin sulfate (7.5 mg./Kg.)
Number of subjects: 50
Study: 30871549

Group type: EXPERIMENTAL
Intervention: Insoles with LLD correction (70% correction of LLD) used for 8 hours per day
Number of subjects: 387

Group type: COMPARATOR
Intervention: Insoles without LLD correction
Number of subjects: 387
Study: 27884722

Group type: EXPERIMENTAL
Intervention: Sequential anthracycline-taxane chemotherapy
Number of subjects: 1363

Group type: COMPARATOR
Intervention: Epirubicin/fluorouracil/cyclophosphamid chemotherapy (FEC)
Number of subjects: 1363
Study: 26498289

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA for 20 min, 5 sessions over 5 consecutive days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham stimulation (5 sessions over 5 consecutive days)
Number of subjects: 22
Study: 24709403

Group type: EXPERIMENTAL
Intervention: 3-dimensional ultrasonography (3DU)
Number of subjects: 75
Study: 23063373

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with Standardized Quality (SQ) 6-grass mix and rye allergen extract, 8-day up-dosing schedule to 10,000 SQ-units (6 daily injections) followed by 2 maintenance injections of 10,000 SQ-units at intervals of 2 and 4 weeks.
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 20218422

Group type: EXPERIMENTAL
Intervention: Elevated serum TRACP-5b levels
Number of subjects: 820

Group type: COMPARATOR
Intervention: Control group (asymptomatic subjects)
Number of subjects: 820
Study: 17534231

Group type: EXPERIMENTAL
Intervention: Biphasic electrical stimulation up to 20 ma for 30 minutes, 3 times a week for 4 weeks in a 32 degrees C room.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Biphasic electrical stimulation in a warm room.
Number of subjects: 20
Study: 15157949

Group type: EXPERIMENTAL
Intervention: Narcoleptics
Number of subjects: 39

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 39
Study: 11522698

Group type: EXPERIMENTAL
Intervention: Inhaled insulin regimen
Number of subjects: 69

Group type: COMPARATOR
Intervention: Subcutaneous insulin regimen
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: HbA(1c) change
Number of subjects: 69
Study: 9478090

Group type: EXPERIMENTAL
Intervention: Workers producing organophosphorous pesticides
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Workers producing chlorfenvinphos
Number of subjects: 120
Study: 7944467

Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy with MTX, ADR, and CDDP
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High dose of CDDP (more than 100 mg/m2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy (general)
Number of subjects: 88
Study: 2886223

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Benztropine
Number of subjects: 22
Study: 28833613

Group type: EXPERIMENTAL
Intervention: Immediately provisionalised with a non-occluding temporary crown
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (left without a crown)
Number of subjects: 24
Study: 27655326

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied before plyometric exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied after plyometric exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 24597534

Group type: EXPERIMENTAL
Intervention: Primary care intervention to reduce sitting time over six months (Intervention Group - IG)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Primary care intervention to reduce sitting time (Intervention Group - IG)
Number of subjects: 232
Study: 23113898

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise (n = 25), 90 min/d, 2 d/wk for 12 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Education control group (n = 25)
Number of subjects: 50
Study: 20561460

Group type: EXPERIMENTAL
Intervention: Interactive educational workshop and chart audit with feedback on cholesterol management
Number of subjects: 340

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 340
Study: 16973692

Group type: EXPERIMENTAL
Intervention: Face Cooling (FC)
Number of subjects: 10
Study: 16351360

Group type: EXPERIMENTAL
Intervention: African American prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number 7 prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low self-monitors
Number of subjects: 0
Study: 12081819

Group type: EXPERIMENTAL
Intervention: 30 g isolated soy protein (ISP)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 50 g isolated soy protein (ISP)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Casein
Number of subjects: 130
Study: 7560560

Group type: EXPERIMENTAL
Intervention: Multiple-gate screening procedure
Number of subjects: 7231

Group type: EXPERIMENTAL
Intervention: Positive screens
Number of subjects: 7231

Group type: EXPERIMENTAL
Intervention: Negative screens
Number of subjects: 7231

Group type: COMPARATOR
Intervention: Low-risk comparison children
Number of subjects: 7231

Group type: EXPERIMENTAL
Intervention: Gating measures
Number of subjects: 7231

Group type: EXPERIMENTAL
Intervention: Family process variables (poor family communication, poor maternal coping skills, external parent locus of control)
Number of subjects: 7231
Study: 2096603

Group type: EXPERIMENTAL
Intervention: Lyophilized bovine pericardium
Number of subjects: 102

Group type: COMPARATOR
Intervention: Lyophilized human dura mater
Number of subjects: 102
Study: 556111

Group type: EXPERIMENTAL
Intervention: Anxiety Management Training (AMT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 14
Study: 31301191

Group type: EXPERIMENTAL
Intervention: Music & Memory program (individualized music delivered at early signs of agitation)
Number of subjects: 45
Study: 28864134

Group type: EXPERIMENTAL
Intervention: Left cardiac sympathetic denervation (LCSD) as an adjunct to guideline recommended medical therapy
Number of subjects: 4

Group type: COMPARATOR
Intervention: Guideline recommended medical therapy
Number of subjects: 4
Study: 26945176

Group type: EXPERIMENTAL
Intervention: 1‐DAY ACUVUE DEFINE (AD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1‐DAY ACUVUE DEFINE with Lacreon (ADL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1‐DAY ACUVUE MOIST (AM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No Lens Wear (NLW)
Number of subjects: 24
Study: 23725997

Group type: EXPERIMENTAL
Intervention: Concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ)
Number of subjects: 15
Study: 21214392

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using a 50 mW 660 nm GaAlAs laser, irradiated at 1.75 W/cm² for 28 seconds per point, at three points around the cryosurgical site, immediately after treatment and at 48 and 72 hours post-treatment.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cryosurgical treatment without LLLT (Non-LLLT group).
Number of subjects: 18
Study: 19447369

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using a bioadhesive patch loaded with 38 mg cm(‐2) aminolevulinic acid, administered in one or two cycles.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using a bioadhesive patch loaded with 38 mg cm(‐2) aminolevulinic acid.
Number of subjects: 23
Study: 17277911

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15717704

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg kg(‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg(‐1)
Number of subjects: 40
Study: 11258644

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g dose, 2 hours before exercise)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9696472

Group type: EXPERIMENTAL
Intervention: MMPI-2 assessment
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: External measures relevant to pain
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MMPI-2 dimensions
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MMPI-2 research
Number of subjects: 240
Study: 8026290

Group type: EXPERIMENTAL
Intervention: Polymeric dressing
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional wet‐to‐dry saline dressings
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional therapy (crossed over to polymeric dressing)
Number of subjects: 19
Study: 2531184

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of cilazapril and propranolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cilazapril alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combination of both drugs
Number of subjects: 18
Study: 4564559

Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (10^6.4 TCID(50))
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (10^6.8 TCID(50))
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (10^4.6 TCID(50))
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (10^2.4 TCID(50))
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 27
Study: 31556131

Group type: EXPERIMENTAL
Intervention: Elevated BP at 28 weeks’ gestation
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Elevated BP at 34 weeks’ gestation
Number of subjects: 329

Group type: COMPARATOR
Intervention: Normal BP in pregnancy
Number of subjects: 329
Study: 28538676

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Habitual diet (HabDiet)
Number of subjects: 166
Study: 24115184

Group type: EXPERIMENTAL
Intervention: Calcium 2000 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D3 800 IU/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium 2000 mg/d and Vitamin D3 800 IU/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23845522

Group type: EXPERIMENTAL
Intervention: CPRO device
Number of subjects: 24

Group type: COMPARATOR
Intervention: MCPR
Number of subjects: 24
Study: 21934308

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted gastrectomy (LAG)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Open gastrectomy (OG)
Number of subjects: 123
Study: 19537528

Group type: EXPERIMENTAL
Intervention: Test formulation (generic alternative)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Reference formulation (standard preparation)
Number of subjects: 72
Study: 16740440

Group type: EXPERIMENTAL
Intervention: Daily supplementation (DS) - 60 mg iron, 200 mcg folic acid, 1 mcg vitamin B12 daily
Number of subjects: 116

Group type: COMPARATOR
Intervention: Weekly supplementation (WS) - two tablets once weekly
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Hemoconcentration (both groups)
Number of subjects: 116
Study: 15327611

Group type: EXPERIMENTAL
Intervention: New cervical cell sampler (the implement)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Jordan's spatula (control)
Number of subjects: 220
Study: 11526270

Group type: EXPERIMENTAL
Intervention: ECG trigger at 40% (group 1)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: ECG trigger at 50% (group 2)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: ECG trigger at 60% (group 3)
Number of subjects: 274

Group type: COMPARATOR
Intervention: ECG trigger at 80% (group 4)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Untriggered group (group 5)
Number of subjects: 274
Study: 9547830

Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other factors (e.g., heredity, social class, maternal age, etc.)
Number of subjects: 0
Study: 11271215

Group type: EXPERIMENTAL
Intervention: Pretransplant blood transfusions (at least three random blood transfusions), n = 86
Number of subjects: 171

Group type: COMPARATOR
Intervention: No pretransplant transfusion, n = 85
Number of subjects: 171
Study: 3418689

Group type: EXPERIMENTAL
Intervention: Direct-mail campaign
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 99
Study: 29133549

Group type: EXPERIMENTAL
Intervention: RG7667 (10 mg/kg of each antibody, 4 doses at transplant, 1, 4, and 8 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (n = 60)
Number of subjects: 120
Study: 28786337

Group type: EXPERIMENTAL
Intervention: In-reach rehabilitation team
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 214
Study: 25105458

Group type: EXPERIMENTAL
Intervention: Dried fermentate (EpiCor(®))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study: 23660846

Group type: EXPERIMENTAL
Intervention: Transcranial laser therapy (TLT)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 640
Study: 21367352

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg at bedtime
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18714238

Group type: EXPERIMENTAL
Intervention: Serial Concurrent Exercise (CE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Integrated Concurrent Exercise (CE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Integrated CE
Number of subjects: 50
Study: 16526898

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) signals measured in healthy adults over 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIRS signal amplitudes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distance between activation centers identified in two sessions
Number of subjects: 0
Study: 12882067

Group type: EXPERIMENTAL
Intervention: 10 mg of metoclopramide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gastric insufflation of 350 mL of air
Number of subjects: 60
Study: 10837440

Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg bd for 5 days
Number of subjects: 548

Group type: COMPARATOR
Intervention: Cefprozil 500 mg bd for 10 days
Number of subjects: 548
Study: 10203402

Group type: EXPERIMENTAL
Intervention: 5 g MgSO4
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 8410924

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 28
Study: 3011885

Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 (100 micrograms)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 (random infusion)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline (random infusion)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ACTH 1‐17
Number of subjects: 19
Study: 29029053

Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 2084
Study: 27887581

Group type: EXPERIMENTAL
Intervention: Therapist guided Internet-based CBT program
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Self-management Internet-based CBT program
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual care, waiting list control group
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Both Internet-based CBT programs (therapist guided and self-management)
Number of subjects: 248
Study: 24507091

Group type: EXPERIMENTAL
Intervention: Rifampicin 300 mg twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (50 mg riboflavin capsules)
Number of subjects: 100
Study: 23648372

Group type: EXPERIMENTAL
Intervention: Cannabis (115 mg Δ9-THC, twice daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (cannabis flowers with THC extracted)
Number of subjects: 21
Study: 21677596

Group type: EXPERIMENTAL
Intervention: High acculturation
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Low acculturation
Number of subjects: 504
Study: 18971605

Group type: EXPERIMENTAL
Intervention: Early Enteral Nutrition (EEN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Early Natural Nutrition (ENN)
Number of subjects: 60
Study: 16610922

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 485

Group type: COMPARATOR
Intervention: Oxycodone-acetaminophen
Number of subjects: 485
Study: 12544676

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 11712308

Group type: EXPERIMENTAL
Intervention: Amilorid (10 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (500 mg)
Number of subjects: 41
Study: 8793307

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg three times daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 61
Study: 1451725

Group type: EXPERIMENTAL
Intervention: MK-571 (L-660,711) administered intravenously, single doses up to 1500 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MK-571 (L-660,711) administered orally, multiple doses of 100, 300, and 600 mg t.i.d. for 31 doses
Number of subjects: 26
Study: 6837255

Group type: EXPERIMENTAL
Intervention: 20 ml mepivacaine with adrenaline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 40 ml mepivacaine with adrenaline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 80 ml mepivacaine with adrenaline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups (20 ml, 40 ml, 80 ml)
Number of subjects: 150
Study: 31594062

Group type: EXPERIMENTAL
Intervention: CCLG-ALL 2008 protocol
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CCLG-ALL 2008 protocol (intermediate risk group)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CCLG-ALL 2008 protocol (high risk group)
Number of subjects: 84
Study: 29451912

Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib treatment for one or three years
Number of subjects: 400
Study: 26994121

Group type: EXPERIMENTAL
Intervention: Continued thienopyridine
Number of subjects: 3391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3391

Group type: EXPERIMENTAL
Intervention: Thienopyridine plus aspirin (after 12 months)
Number of subjects: 3391
Study: 24605717

Group type: EXPERIMENTAL
Intervention: 30 gram honey
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 75 gram honey
Number of subjects: 97

Group type: COMPARATOR
Intervention: 75 gram glucose
Number of subjects: 97
Study: 22252353

Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation (with prebiotic)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low CP level (85% of NRC-recommended level)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Normal stocking density (10 birds/m²)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High stocking density (16 birds/m²)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interactions between protein level and stocking density
Number of subjects: 40
Study: 19837791

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (less intensive training and follow-up)
Number of subjects: 0
Study: 17592346

Group type: EXPERIMENTAL
Intervention: 5 cm H2O positive end-expiratory pressure (PEEP)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No PEEP (Control Group)
Number of subjects: 53
Study: 15833301

Group type: EXPERIMENTAL
Intervention: Reach-first intervention (infants grasp objects before watching another person grasp similar objects)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watch-first intervention (infants watch another person grasp similar objects before grasping objects themselves)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engagement in object-directed contact with toys
Number of subjects: 0
Study: 11872654

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caffeine and Exercise
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 7
Study: 10195381

Group type: EXPERIMENTAL
Intervention: Metformin (MET) 500 mg twice daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (DEX) 15 mg thrice daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All groups (MET, DEX, Placebo)
Number of subjects: 28
Study: 8547378

Group type: EXPERIMENTAL
Intervention: Regular follow-up visits by a geriatric team at 1, 3, 8 and 16 weeks after discharge
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 193
Study: 2317464

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intravenous phenytoin sodium
Number of subjects: 22
Study: 7364321

Group type: EXPERIMENTAL
Intervention: Oral prednisone (0.3 mg per kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (0.3 mg per kg)
Number of subjects: 14
Study: 29558241

Group type: EXPERIMENTAL
Intervention: Prism adaptation treatment for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 31068272

Group type: EXPERIMENTAL
Intervention: Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg
Number of subjects: 657

Group type: COMPARATOR
Intervention: Dolutegravir 50 mg with co-formulated emtricitabine 200 mg and tenofovir alafenamide 25 mg
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Bictegravir group
Number of subjects: 657

Group type: COMPARATOR
Intervention: Dolutegravir group
Number of subjects: 657
Study: 26857103

Group type: EXPERIMENTAL
Intervention: SCION-HSCT intervention (standard care plus SCION-HSCT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 79